# Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)

> **NCT01782963** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 50 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01782963
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2016-12
- **Final completion:** 2017-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01782963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01782963, "Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01782963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*